SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Akari Therapeutics, Plc - FDA Agrees to Use of New Higher-Yielding Manufacturing Process for Nomacopan in Pivotal Clinical Studies

01/20/2022 | 09:33am EDT

NEW YORK and LONDON - Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement (C5) and/or leukotriene (LTB4) systems are implicated, announced that the U.S. Food and Drug Administration (FDA) has agreed, via a Type C meeting, to the clinical use of nomacopan derived from a next generation manufacturing process. Nomacopan is Akari's lead drug candidate currently in two Phase III programs.

The FDA agreed that the new manufacturing process produces drug that is comparable to nomacopan from the prior manufacturing process. The new manufacturing process increases the final yield of nomacopan at least 5-fold, compared to the previous manufacturing process, which will significantly decrease future commercial cost of goods and reduce the cost of ongoing Phase II/III and future clinical development programs for nomacopan.

'FDA's agreement for our use of the new and enhanced manufacturing process is a key milestone in the pathway to commercialization of nomacopan,' said Miles Nunn, Ph.D., Chief Scientific Officer of Akari Therapeutics. 'The FDA's agreement is the culmination of several years' work, and I would like to thank Akari's Head of CMC, Mukesh Sehdev, and our long-term partners in the manufacture of nomacopan, Wacker Biotechnology GmbH and Solvias AG, for their strategic planning, commitment and the quality of their work.'

About Akari Therapeutics

Akari is a biopharmaceutical company focused on developing inhibitors of acute and chronic inflammation, specifically for the treatment of rare and orphan diseases, in particular those where the complement (C5) or leukotriene (LTB4) systems, or both complement and leukotrienes together, play a primary role in disease progression. Akari's lead drug candidate, Nomacopan (formerly known as Coversin), is a C5 complement inhibitor that also independently and specifically inhibits leukotriene B4 (LTB4) activity. Nomacopan is currently being clinically evaluated in four areas: bullous pemphigoid (BP), thrombotic microangiopathy (TMA), as well as programs in the eye and lung.

Cautionary Note Regarding Forward-Looking Statements

Certain statements in this press release constitute 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. Although we believe that our plans, intentions, expectations, strategies and prospects as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond our control. Such risks and uncertainties for our company include, but are not limited to: needs for additional capital to fund our operations, our ability to continue as a going concern; uncertainties of cash flows and inability to meet working capital needs; an inability or delay in obtaining required regulatory approvals for Nomacopan and any other product candidates, which may result in unexpected cost expenditures; our ability to obtain orphan drug designation in additional indications; risks inherent in drug development in general; uncertainties in obtaining successful clinical results for Nomacopan and any other product candidates and unexpected costs that may result therefrom; difficulties enrolling patients in our clinical trials; our ability to enter into collaborative, licensing, and other commercial relationships and on terms commercially reasonable to us; failure to realize any value of Nomacopan and any other product candidates developed and being developed in light of inherent risks and difficulties involved in successfully bringing product candidates to market; inability to develop new product candidates and support existing product candidates; the approval by the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) and any other similar foreign regulatory authorities of other competing or superior products brought to market; risks resulting from unforeseen side effects; risk that the market for Nomacopan may not be as large as expected; risks associated with the impact of the COVID-19 pandemic; inability to obtain, maintain and enforce patents and other intellectual property rights or the unexpected costs associated with such enforcement or litigation; inability to obtain and maintain commercial manufacturing arrangements with third party manufacturers or establish commercial scale manufacturing capabilities; the inability to timely source adequate supply of our active pharmaceutical ingredients from third party manufacturers on whom the company depends; unexpected cost increases and pricing pressures and risks and other risk factors detailed in our public filings with the Securities and Exchange Commission (SEC), including our most recently filed Annual Report on Form 20-F filed with the SEC. Except as otherwise noted, these forward-looking statements speak only as of the date of this press release and we undertake no obligation to update or revise any of these statements to reflect events or circumstances occurring after this press release. We caution investors not to place considerable reliance on the forward-looking statements contained in this press release.



Peter Vozzo

ICR Westwicke

T: (443) 213-0505

E: peter.vozzo@westwicke.com


Sukaina Virji

Maya Bennison

Consilium Strategic Communications

T: +44 (0)20 3709 5700

E: Akari@consilium-comms.com

(C) 2022 Electronic News Publishing, source ENP Newswire

11:07aEuropean ADRs Move Higher in Thursday Trading
05/25European ADRs Move Lower in Wednesday Trading
05/20AKARI THERAPEUTICS : Presents Results from the CASCADE and CORONET Studies in COVID-19 at ..
05/19Akari Therapeutics Presents Results from the CASCADE and CORONET Studies in COVID-19 at..
05/19Akari Therapeutics, Plc Presents Results from the CASCADE and CORONET Studies in COVID-..
05/19European ADRs Move Higher in Thursday Trading
05/19AMERICAN THORACIC SOCIETY (AST) ANNU : “Identification of Clinical Deterioration Ris..
05/18European ADRs Move Lower in Wednesday Trading
05/17Akari Therapeutics, Plc Reports Earnings Results for the Full Year Ended December 31, 2..
05/16Akari Therapeutics Reports Full Year 2021 Financial Results and Highlights Clinical Pro..
More news
Financials (USD)
Sales 2022
Net income 2022
Net Debt 2022
P/E ratio 2022
Yield 2022
Capitalization 72,4 M 72,4 M -
EV / Sales 2022
Capi. / Sales 2023 -
Nbr of Employees 9
Free-Float 80,0%
Duration : Period :
Akari Therapeutics, Plc Technical Analysis Chart | AKTX | US00972G1085 | MarketScreener
Technical analysis trends AKARI THERAPEUTICS, PLC
Short TermMid-TermLong Term
Income Statement Evolution
EPS Revisions
Managers and Directors
Rachelle Jacques President, Chief Executive Officer & Director
Torsten Hombeck Chief Financial & Accounting Officer
Raymond Prudo-Chlebosz Executive Chairman
Miles Nunn Chief Scientific Officer
Wynne Weston-Davies Medical Director
Sector and Competitors
1st jan.Capi. (M$)
GILEAD SCIENCES, INC.-11.21%81 543
WUXI APPTEC CO., LTD.-25.70%39 423
BIONTECH SE-40.00%37 588